In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1259-1267

  Pucci, Michael J ^a   Cheng, Jijun ^a   Podos, Steven D ^a   Thoma, Christy L ^a   Thanassi, Jane A ^a   Buechter, Douglas D ^a   Mushtaq, Gohar ^a   Vigliotti Jr , Gerald A ^a   Bradbury, Barton J ^a   Deshpande, Milind ^a  

^a Achillion Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BACTERIAL DNA; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ETHIDIUM BROMIDE; GEMIFLOXACIN; IMIPENEM; ISOTHIOAZOLONE DERIVATIVE; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MINOCYCLINE; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; TETRACYCLINE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE MODEL; DNA REPLICATION; DRUG EFFECT; DRUG EFFICACY; ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; LEGIONELLA PNEUMOPHILA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MOUSE; MYCOPLASMA PNEUMONIAE; NEISSERIA; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; SEPSIS; STAPHYLOCOCCUS;

ANIMALS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; MICE; MICROBIAL SENSITIVITY TESTS; QUINOLONES; THIAZOLES;

EID: 34247170756     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01315-06     Document Type: Article

References (28)

1. Appelbaum, P. C. 2006. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12(Suppl. 1):16-23.
2. Bogdanovich, T., D. Esel, L. M. Kelley, B. Bozdogan, K. Credito, G. Lin, K. Smith, L. M. Ednie, D. B. Hoellman, and P. Appelbaum. 2005. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Antimicrob. Agents Chemother. 49:325-3333.
3. Centers for Disease Control and Prevention. 1997. Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. JAMA 278:1145-1146.
4. Centers for Disease Control and Prevention. 2002. Vancomycin resistant Staphylococcus aureus-Pennsylvania, 2002. JAMA 288:2116.
5. Chambers, H. F. 2005. Community-associated MRSA-resistance and virulence converge. N. Engl. J. Med. 352:1485-1487.
6. Chu, D. T., P. B. Fernandes, A. K. Claiborne, L. Shen, and A. G. Pernet. 1988. Structure-activity relationships in quinolone antibacterials: design, synthesis, and biological activities of novel isothiazoloquinolones. Drugs Exp. Clin. Res. 14:379-383.
7. Chu, D. T., I. M. Lico, A. K. Claiborne, J. J. Plattner, and A. G. Pernet. 1990. Structure-activity relationship of quinolone antibacterial agents: the effects of C-2 substitution. Drugs Exp. Clin. Res. 16:215-224.
8. Courvalin, P. 2006. Vancomycin resistance in gram-positive cocci. Clin. Infect. Dis. 42(Suppl. 1):S25-S34.
9. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams & Wilkins Co., Baltimore, MD.
10. Gudmundsson, A., H. Erlendsdottir, M. Gottfredsson, and S. Gudmundsson. 1991. Impact of pH and cationic supplementation on in vitro postantibiotic effect. Antimicrob. Agents Chemother. 35:2617-2624.
11. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
12. Jones, M. E., R. S. Blosser-Middleton, C. Thornsberry, J. A. Karlowsky, and D. F. Sahm. 2003. The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002. Diagn. Microbiol. Infect. Dis. 47:579-586.
13. Lawrence, L. E., M. Frosco, B. Ryan, S. Chaniewski, H. Yang, D. C. Hooper, and J. F. Barrett. 2002. Bactericidal activities of BMS-284756, a novel des-F(6)-fluoroquinolone, against Staphylococcus aureus strains with topoisomerase mutations. Antimicrob. Agents Chemother. 46:191-195.
14. Low, D. E., M. Muller, C. L. Duncan, B. M. Willey, J. C. de Azavedo, A. McGeer, B. N. Kreiswirth, S. Pong-Porter, and D. J. Bast. 2002. Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance. Anti-microb. Agents Chemother. 46:1119-1121.
15. McDonald, L. C. 2006. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin. Infect. Dis. 42(Suppl. 2):S65-S71.
16. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 6th ed. M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
17. National Committee for Clinical Laboratory Standards. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 6th ed. M11-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
18. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1994. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus located on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. 38:1345-1355.
19. Nikaido, H. 1998. Multiple antibiotic resistance and efflux. Curr. Opin. Microbiol. 1:516-523.
20. Pankush, G. A., and P. C. Appelbaum. 2005. Postantibiotic effect of DX-619 against 16 gram-positive organisms. Antimicrob. Agents Chemother. 49:3963-3965.
21. Patterson, D. L., and R. A. Bonomo 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
22. Poole, K. 2004. Resistance to beta-lactam antibiotics. Cell. Mol. Life Sci. 61:2200-2223.
23. Pucci, M. J., J. J. Bronson, J. F. Barrett, K. L. DenBleyker, L. F. Discotto, J. C. Fung-Tomc, and Y. Ueda. 2004. Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibiotics. Antimicrob. Agents Chemother. 48:3697-3701.
24. Truong-Bolduc, Q. C., P. M. Dunman, J. Strahilevitz, S. J. Projan, and D. C. Hooper. 2005. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J. Bacteriol. 187:2395-2405.
25. Waites, K. B., L. B. Duffy, T. Schmid, D. Crabb, M. S. Pate, and G. H. Cassell. 1991. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrob. Agents Chemother. 35:1181-1185.
26. Wang, Q., E. Lucien, A. Hashimoto, G. C. G. Pais, D. M. Nelson, Y. Song, J. A. Thanassi, C. W. Marlor, C. L. Thoma, J. Cheng, S. D. Podos, Y. Ou, M. Deshpande, M. J. Pucci, D. D. Buechter, B. J. Bradbury, and J. A. Wiles. 2007. Isothiazoloquinolones with enhanced antistaphylococcal activities against multi-drug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions. J. Med. Chem. 50:199-210.
27. Wiles, J. A., Q. Wang, E. Lucien, A. Hashimoto, Y. Song, J. Cheng, C. Marlor, Y. Ou, S. D. Podos, J. A. Thanassi, C. L. Thoma, M. Deshpande, M. J. Pucci, and B. J. Bradbury. 2005. Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. Bioorg. Med. Chem. Lett. 16:1272-1276.
28. Wiles, J. A., Y. Song, Q. Wang, E. Lucien, A. Hashimoto, C. Marlor, Y. Ou, S. D. Podos, J. A. Thanassi, C. L. Thoma, M. Deshpande, M. J. Pucci, and B. J. Bradbury. 2006. Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: in vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus. Bioorg. Med. Chem. Lett. 16:1277-1281.